Table 1.

Newer immunosuppression protocol in ICT.

Protocol Induction	Maintenance	n	Reported adverse events		Reference
ATG (basiliximab for 2nd Tx) + belatacept	Sirolimus ± MMF	5	(Both belatacept and efalizumab group)	Oral ulcer (many), nausea (3), diarrhea (4), neutropenia (3), thrombocytepenia (1),Rash or erythema (2)	6, 7
ATG (basiliximab for 2nd Tx) + efalizumab	Sirolimus ± MMF	5	(Efalizuma b group)	Rash/Erythema (2), partial portal vein thrombosis (1)
ATG + etanercept	Cyclosporine + everolimus or MMF	6	Oral ulcer (6), leukopenia (6), transient elevations of liver enzymes (6), acute cholecystitis (2), increased serum creatinine (6), >25% decreased GFR (2), hypertension (1), hyperlipidemia (1)		4
ATG + daclizumab + etanercept	MMF + sirolimus ± low-dose tacrolimus	8	Lymphopenia (5), transient neutropenia (5), oral ulcer (8)		61
Alemtuzumab + etanercept	Sirolimus + tacrolimus/MMF	3	Leukopenia (3), lymphopenia (3), Skin rash (3)		5
Daclitumab ± infliximab,	Sirolimus + tacrolimus	16	Aspication pneumonia (1), parvovirus infection (1), HES (1), short-term memory loss 1), renal dysfunction (1), exzema (1) and insomnnia/depression (1), Leukopenia/neutropenia (9), serum creatinine elevation (2), macroalbuminuria (5), mild hypertension (1), hyperlipidemia (14), mouth ulcer, peripheral edema, insomnia, tremor, anxiety, headache, gynecological abnormalities, bone marrow suppression, electrolyte abnormalities, proteinuria		62
Daclitumab + etanercept + exenatide	Sirolimus + tacrolimus	6	Weight loss (6), nausea (6), vomitting (6), viral stomatitis (1), severe anemia (1), elevated creatinine (2), myonecrosis (1)		63
Daclitumab + Efalizumab	MMF + tacrolimus	4	Anemia (2), elevation of liver enzymes (2),		8

The numbers in parentheses indicate number of patients with individual AE.